G. Serikbayev

G. Serikbayev

Auto-generated profile, based on publicly available information

G. Serikbayev

«Kazakh Institute of Oncology and Radiology» JSC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
DTD. Tuleuova
D. Tuleuova
GSG. Serikbayev
G. Serikbayev
АKА. Kurmanalyev
А. Kurmanalyev
ZPZ. Pyssanova
Z. Pyssanova
АYА. Yelekbayev
А. Yelekbayev
Relevance: Sarcomas are a heterogeneous group of malignant neoplasms (MNs) of mesenchymal origin. The peak incidence of bone tumors falls on a socially significant age: with osteosarcoma and Ewing’s sarcoma – 10-25 years, with chondrosarcoma – 35-40 years. Bone sarcomas are the most aggressive human MNs. This urges to determine the prognostic factors of the disease, timely assess the treatment effect, and identify possible relapses. The study aimed to improve the early diagnosis of bone sarcomas, to improve and increase the oncological alertness of doctors by establishing the trends in bone sarcoma incidence and mortality in the Republic of Kazakhstan in 2010-2019, and this disease incidence and mortality in 2019 by age, gender, bone tumor histotype and region of the country. Methods: The study included the data of patients registered at the RK National Cancer Registry in 2010-2019 with a “bone sarcoma” diagnosis (ICD-10 code: C40-C41). The incidence of bone sarcomas was presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality were calculated using the World Standard. MS Excel 2016 was used to display the results graphically. Results: By the end of 2019, 1587 patients were registered with bone sarcomas in the RK. From 2010 to 2019, the incidence of bone sarcoma in the RK decreased by 39%, including 36% among men and 40% among women. Mortality decreased by 37% to 0.8% per 100,000 population. Bone sarcoma is not among the 20 most common types of cancer in the RK; it accounts for 0.7% of all new cases of MN (2010-2019). The peak incidence of bone sarcoma was observed at the age below 20 years (20%), and mortality – in the age group of 45-54 years (22%). Conclusion: The rare occurrence of bone MNs can cause misdiagnosis during the initial examination. Bone sarcomas account for 0.8% of all MNs diagnosed in the RK; however, the aggressiveness of the course and rapid hematogenous metastasis causes a high percentage of neglect of this disease during the initial visit. In addition, bone sarcomas are more common than other MNs in young adults and adolescents. The prognosis of primary bone sarcomas depends on many factors.

29 March 2024 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
DTD. Tuleuova
D. Tuleuova
GSG. Serikbayev
G. Serikbayev
АKА. Kurmanalyev
А. Kurmanalyev
ZPZ. Pyssanova
Z. Pyssanova
АYА. Yelekbayev
А. Yelekbayev
Relevance: Skin cancer, including melanoma, is a major health problem and one of the most common cancers in the world. The study aimed to obtain a complete epidemiological picture of skin cancer and melanoma in the Republic of Kazakhstan for 11 years, including analysis of data for 2022, considering various parameters such as age, sex, ethnicity, region, and tumor type. Methods: The study used data from patients registered in the national cancer registry of the Republic of Kazakhstan from 2012 to 2022, diagnosed with skin carcinoma and skin melanoma (ICD-10 code: C44-C43). The number of skin carcinomas and melanoma cases is presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality rates were calculated using the world standard (World). Results: At the end of 2022, 19,714 and 2,689 patients were diagnosed with “Skin Cancer” or “Skin Melanoma” in the Republic of Kazakhstan, respectively. From 2012 to 2022, the incidence of skin cancer increased by 24% and melanoma by 15%. In 2022, the incidence of skin cancer and melanoma was higher among women by 24% and 26%, respectively. Mortality from skin cancer is in 23rd place, from melanoma in 21st place. Mortality rates from skin cancer and melanoma were 0.5 and 0.7 per 100 thousand population, respectively. The peak incidence of skin cancer in 2022 was observed in the age group 65-74 years (36%), and mortality in the age groups 65-74 and 75-84 years (17% each). The peak incidence of skin melanoma in 2022 was observed in the age groups 55-64 years and 65-74 years (24% and 25%), and mortality in the groups 45-54 years and 35-44 years (14% and 10%). Conclusion: There has been a steady increase in the incidence of skin cancer and melanoma, which indicates the seriousness of this problem in the country and underlines the need for further measures to prevent, diagnose and treat skin cancer and melanoma in the Republic of Kazakhstan. It should be remembered that many cases of skin cancer can be prevented with simple precautions.

30 June 2024 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
GSG. Serikbaev
G. Serikbaev
AKA. Kurmanaliev
A. Kurmanaliev
ZPZ. Pysanova
Z. Pysanova
RKR. Kadyrbaeva
R. Kadyrbaeva
ZMZh. Mayukova
Zh. Mayukova
AAA. Adilkhanova
A. Adilkhanova
Relevance: Myopericytoma is a soft tissue tumor characterized by the proliferation of myopericytes. The tumor originates from myoid cells localized in the skin and soft tissues. Usually, this tumor is benign, but in rare cases, it can be malignant. Myopericytoma is a rare neoplasm, so specific data on its prevalence around the world are limited. The article presents a clinical case of retroperitoneal myopericytoma and a review of the cases described in the literature to analyze the epidemiology and clinical characteristics. Accurate data on the global prevalence of myopericytoma are not available due to the rarity of the disease and the difficulties of diagnosis. Thus, the study of myopericytoma has significant relevance, as it contributes to a better understanding and management of this rare soft tissue tumor and improves patients’ quality of life. The study aimed to describe a clinical case of retroperitoneal soft tissue myopericytoma in a 27-year-old patient. Methods: The authors present a clinical case of retroperitoneal soft tissue myopericytoma. The descriptions of the other 50 clinical cases of myopericytoma were found in the PubMed, Cochrane Library, eLibrary, CyberLeninka, and Google Scholar electronic databases, including the results of clinical examination, computed tomography (CT) and magnetic resonance imaging (MRI), and histopathological examination of biopsy material. Results: A 27-year-old girl went to the clinic complaining of pressure pains in the lower abdomen. A formation in the retroperitoneal space was revealed after a comprehensive examination, including CT and MRI. Further, soft tissue biopsies of the retroperitoneal space were performed, and the diagnosis of myopericytoma was confirmed. The patient was successfully surgically removed from the tumor. Conclusion: Myopericytomas, although classified as benign tumors, pose a serious problem due to their tendency to relapse. Despite their slow growth, they can reach significant sizes and grow into surrounding structures and organs. Consequently, the experience and skill of surgeons play an important role in the vastness of surgical intervention for radical tumor removal, which is important for the patient’s prognosis and quality of life. Radical surgical treatment for myopericytoma is especially important because it allows the complete removal of the neoplasm and minimizes the risk of recurrence, thereby improving long-term results and reducing the need for additional therapeutic interventions.

31 March 2022 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
DTD. Tuleuova
D. Tuleuova
GSG. Serikbayev
G. Serikbayev
АKА. Kurmanalyev
А. Kurmanalyev
ZPZ. Pyssanova
Z. Pyssanova
АYА. Yelekbayev
А. Yelekbayev
Relevance: Sarcomas are a heterogeneous group of mesenchymal origin malignant neoplasms (MNs). The peak incidence of bone tumors falls at a socially significant age: with osteosarcoma and Ewing’s sarcoma – 10-25 years, with chondrosarcoma – 35-40 years. Bone sarcomas are the most aggressive human MNs. This urges to determine the prognostic factors of the disease, timely assess the treatment effect, and identify possible relapses. The study aimed to improve the early diagnosis of bone sarcomas, to improve and increase the oncological alertness of doctors by establishing the trends in bone sarcoma incidence and mortality in Kazakhstan in 2010-2019 and this disease incidence and mortality in 2019 by age, gender, bone tumor histotype and region of the country. Materials and Methods: This study included the data of all patients registered at the Electronic Registry of Oncological Patients (EROP) of the Republic of Kazakhstan in 2010-2019 with a “bone sarcoma” diagnosis (ICD-10 code: C40-C41). The incidence of bone sarcomas was presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality were calculated using the World Standard. MS Excel 2016 was used to display the results graphically. Results: By the end of 2019, 1587 patients were registered with bone sarcomas in Kazakhstan. From 2010 to 2019, the incidence of bone sarcoma in Kazakhstan decreased by 39%, including 36% among men and 40% among women. Mortality decreased by 37% to 0.7% per 100,000 population. Bone sarcoma is not among the 20 most common types of cancer in Kazakhstan. It accounts for 0.7% of all new cases of MN (2010-2019). The peak incidence of bone sarcoma was observed at the age below 20 years (20%), and mortality – was registered at 45-54 years (22%). Conclusion: The rare occurrence of bone MNs can cause misdiagnosis during the initial examination. Bone sarcomas account for 0.8% of all MNs diagnosed in Kazakhstan. However, the aggressiveness of the course and rapid hematogenous metastasis causes a high percentage of neglect of this disease during the initial visit. In addition, bone sarcomas are more common than other MNs in young adults and adolescents. Therefore, the prognosis of primary bone sarcomas depends on many factors.